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ABSTRACT 
This paper investigates the regulation of bioprospecting in Brazil, examining especially 
the appropriateness of the legislation in relation to the principles of the Convention on 
Biological Diversity (CBD) and the Trade-Related Aspects of Intellectual Property 
Rights (TRIPS). It also discusses the situation that has been agreed in the covenants 
signed between Brazil and other countries, in view of preserving the diversity and 
integrity of the genetic patrimony of the country. 
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RESUMO 
Este artigo investiga a regulamentação da bioprospecção no Brasil, examinando 
especialmente a adequação da legislação em relação aos princípios da Convenção 
sobre Diversidade Biológica (CBD) e dos Aspectos dos Direitos de Propriedade 
Intelectual Relacionados ao Comércio (TRIPS). Discute também a situação que foi 
acordada nos convênios assinados entre o Brasil e outros países, tendo em vista a 
preservação da diversidade e integridade do patrimônio genético do país. 
 
PALAVRAS-CHAVE: Bioprospecção; Bio-Direito; Contratos; Patrimônio Genético 
 
 
INTRODUCTION 
 
The Federal Constitution of Brazil, when discoursing on art. 225, that all 
individuals have the right to an ecologically balanced environment, of common use, 
and essential to a healthy quality of life, imposes upon the Government and the 
community the duty to defend and preserve it. The first paragraph, section II and the 
fourth paragraph of the said article, set down that "it is for the Government to preserve 
the diversity and integrity of the genetic patrimony of the country and control entities 
engaged in research and manipulation of genetic material, including the use of natural 
resources." 
Thus, Brazil signed on June 5, 1992 the Convention on Biological Diversity 
(CBD) adopted at the United Nations Conference on Environment and Development, 
held in June 1992 in the city of Rio de Janeiro and came into force internationally on 
December 29, 1993. This agreement was approved by the National Congress of Brazil 
through Legislative Decree No. 02 of February 31, 1994, ratified by Brazil on February 
28, 1994 and entered the Brazilian legal system through the enactment of Decree No. 
2,519 of March 16, 1998.  
Provisional Measure No. 2,186-16 of August 23, 2001, aims to regulate the 
section II of paragraph 1 and paragraph 4 of article 225 of the Federal Constitution of 
Brazil, and article 1, article 8 letter "j", article 10 letter "c", articles 15 and 16 paragraphs 
3 and 4 of the Convention on Biological Diversity, which provide for access to genetic 
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resources, protection and access to associated traditional knowledge, benefit sharing, 
as well as access to technology and technology transfer for its conservation and use. 
These genetic resources are having a significant and growing economic importance 
for the development of modern biotechnology with genetic engineering, a technique for 
gene manipulation, as one of its most important areas. 
The above law regulates access to and shipment of samples of genetic 
components and its associated traditional knowledge by public or private entities 
engaged in activities of research and development in the biological and related fields.  
Such bioprospecting creates a unique opportunity that both helps conserve 
biodiversity and preserve social diversity, and serves to promote the development of 
countries that own such resources in view of generating benefits for all parties involved. 
With the most considerable diversity of animals and plants on the planet 
(between 15% and 20% of the total number of species), Brazil occupies a prominent 
role in the debate about the potential of bioprospecting. Some of the richest 
ecosystems in terms of number of species of plants - the Amazon, the Atlantic Forest, 
Pantanal and Cerrado - are located in this country. Brazil is also regarded as a country 
of substantial social diversity, with a very rich set of traditional populations, including 
indigenous peoples, ribeirinhos, caiçaras, seringueiros, among others. These groups 
of people are users of low-impact technology whose knowledge is often a key to 
accessing and exploiting biodiversity resources. 
Beyond its natural wealth and social diversity, Brazil also enjoys other relevant 
advantages, such as a good scientific infrastructure, the availability of human 
resources, as well as universities and public research institutions with the potential to 
lead bioprospecting activities in the country. In addition, Brazil represents a large 
market for pharmaceuticals and is a major participant in world agricultural trade. All 
these features put the Brazilian position in relation to bioprospecting alongside that of 
other major global players such as the United States, European Union and Japan, 
which are the main countries represented in the Amazon region with strong interests 
in its biodiversity. 
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2 THE CONCEPT OF BIOPROSPECTING 
 
Bioprospecting can be defined as the exploitation of biodiversity in view of 
extracting genetic and biochemical resources for economic and social value 
(BEATTIE, 2005). This process can make use of the knowledge of indigenous or 
traditional people (SANT'ANA, 2002) and relies on advanced technologies to develop 
new pharmaceuticals components, agrochemicals, cosmetics, fragrances, industrial 
enzymes, among others. (ARTUSO, 2002). 
As observed by Reid et al. (1993), bioprospecting creates opportunities for the 
governments of countries rich in biodiversity to reap economic benefits from the 
exploitation of their natural wealth, whilst still conserving biodiversity. This would both 
promote the development of countries possessing such resources and generate 
attractive revenue for the industry. 
Bioprospecting can be applied to various activities, impacting different sectors 
of the economy, especially in the fields of pharmaceutics, cosmetology, food and 
agricultural inputs in general. 
The legal principles that ensure bioprospecting as area of knowledge are: i) 
the precautionary principle - in doubt as to irreversible damage the activity should not 
be started or continued, ii) the principle of conservation of resources - resources should 
not be depleted, iii) the principle of distributive equity - the benefits should be shared 
between all parties involved in the activity, iv) the principle of public participation - 
ensuring wider participation of the people involved through public or private entities 
and even individual citizens, v) the principle of transparency - all acts of the activity 
should be transparent to the public, by treating the natural resources and sharing its 
benefits (PAVARINI, 2000). 
The original principle to bioprospecting, that is hitherto accepted by most 
countries, has been that "genetic resources should be available for any and all 
purposes, as end products benefit all societies" (Caillaux& MÜLLER 1998 and 
Azevedo, 2003). However, with the growth of the biotechnology industry and its drive 
towards patenting processes or products developed from such resources, countries 
rich in genetic diversity began to change their attitude regarding the exploitation of 
these resources in order to control their access (Azevedo, 2003).  
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The late 1980s saw a paradigm shift regarding the sovereignty over genetic 
resources. In the early 1990s, the debate on the importance and value of biodiversity 
resurfaced, but this time with a focus on bioprospecting. Since then, the use of 
biodiversity resources has been based on a new paradigm. They include areas like 
information science and technology, and their applications in the production processes 
of companies (Lasmar, 2005). 
To this end, the need arose for an international regime to promote the fair and 
equitable distribution of gains from biodiversity, while taking a systemic view on the 
allocation of these resources (Enriquez, 2005).The general consensus was to establish 
a new international treaty, rather than an ‘umbrella convention’ grouping all existing 
International Conventions on the subject together. The Convention on Biological 
Diversity (CBD) was held in 1992 in the city of Rio de Janeiro in order to form a more 
uniform understanding of the subject. 
With the advent of CBD, new actors have entered into studies and discussions 
on the various manifestations of biodiversity. As a multidimensional activity (a 
collective practice conditioned by other social practices) involving actors as diverse as 
scientists and non-scientists, politicians, academics, industrialists, technologists, 
representatives of indigenous communities, the State, non-governmental 
organizations (NGOs) and various other interest groups, bioprospecting in the field of 
scientific and technological development reveals a myriad of relationships and disputes 
of all kinds (TRIGUEIRO 2006 and DAYS & COSTA, 2008). As noted by Polski (2005), 
the CBD marks the beginning of new relationships between actors using the resources 
and biodiversity conservation. In order to better understand the various groups active 
in the practice of bioprospecting, actors can be divided into the following three 
categories:  
a) Creators of knowledge - actors who most often have prior knowledge of 
bioprospecting and the bioprospecting process. Academic and corporate scientists and 
communities of traditional knowledge such as quilombolas, riparian, fishermen who 
can generate new knowledge, products, processes or applications, or create profitable 
products; 
b) Entrepreneurs – actors bioprospecting biological resources within or outside 
the country in which their enterprises are located (businessmen, farmers, vendors, 
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biotechnologists etc.), with the aim of developing new products, processes and 
profitable applications which can bring this knowledge forward; 
c) Collectors - actors who harvest genetic samples to expand own collection 
or sell to others.  
In view of the high complexity surrounding the practice of bioprospecting, as 
well as the high technological and economic risks that are associated with it, there is a 
need to establish very specific rules or institutions to enable development. Good 
regulation of bioprospecting is essential in order to ensure that it contributes both to 
the conservation of natural resources for economic development of the countries 
involved in the process, as well as to their social development through partnerships 
that lead to shared monetary and non-monetary benefits. In particular, government, 
non-governmental organizations (NGOs), public and private universities, chemical, 
pharmaceutical and other companies as well as communities should participate 
directly through agreements, concessions, permissions and partnerships in general, 
where the responsibilities for all parties involved are clearly defined. 
Despite the growing practice of bioprospecting by theindustry however, only a 
few developing countries have seized the opportunity and begun to exploit their natural 
resources properly. According to Silveira et al. (2004), within this select group of 
countries, Brazil has the preconditions to lead bioprospecting activities in the world 
because of its good scientific and technological infrastructure, the availability of human 
resources, as well as its many universities and public research institutions in life 
sciences. 
 
 
3 TRIPS VERSUS CBD: CONFLICTS AND CONTROVERSIES ON THE WAY TO 
NATIONAL REGULATION 
 
The CBD was created in order to define a sustainable development policy that 
regulates the use of biodiversity resources and the enhancement of traditional 
knowledge. With this purpose in mind, it includes principles for fair and equitable 
sharing of benefits arising from the use of these resources and recognizes the national 
sovereignty of States. 
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However, the implementation of these principles finds itself at odds with certain 
clauses of the TRIPS Agreement. This inherent tension between parts of the CBD and 
TRIPS has yet to be fully eliminated. 
The discrepancies between the TRIPS and CBD agreements are related to 
their respectively different goals and interests. The signatories of both agreements aim 
to pursue a path where bioprospecting is practiced in such a way that it benefits all 
stakeholders without opposing the principles of either agreement.  
According to Guerrante (2003), the main differences and conflicts between the 
TRIPS Agreement and the CBD are:  
• CBD grants to States National the legal capacity to face "biosquatting" with 
prior information. In TRIPS, there is no provision requiring prior informed consent for 
access to biological resources that may later become protected by Intellectual Property 
Rights (IPR). Therefore, ingnoring such a provision serves to encourage biosquatting; 
• According to CBD, National States have sovereign rights over their biological 
resources. This assumes that sovereign countries have the right to prohibit or to 
authorize IPRs on living beings. In TRIPS, biological resources have to be subjected 
to private rights of intellectual property; 
• CBD establishes a legal basis for developing countries to claim their share in 
the benefits arising from the utilization of biological resources and traditional 
knowledge. TRIPS, on the other hand, stipulates that it is necessary to grant patents 
in all fields of technology, therefore, the use and exploitation of biological resources 
are protected by IPRs. However, it provides no mechanism to ensure that benefits are 
shared between the patentee and the resource provider; 
• CBD favors public interest and wellbeing over regards for private property, 
when it stipulates that signatory states are obliged to promote the conservation and 
sustainable use of biodiversity as a common concern for the rights of all humanity. In 
TRIPS, the protection of public health and food safety, as well as public interests in 
general, are subordinated to the private interests of the holders of IPRs. 
These conflicts between the CBD and TRIPS originate in Article 27.3b of 
TRIPS, allowing  intellectual property rights for microorganisms, non-biological and 
microbiological processes. Article 27.3 (b) authorizes member states to exclude, in 
their national legislation, the patenting of plants, animals and essentially biological 
Revista Jurídica                            vol. 04, n°. 49, Curitiba, 2017. pp. 81-100 
                                                                                  DOI: 10.6084/m9.figshare.5632108 
_________________________________________ 
 
88 
 
processes for the production of plants and animals, but obliges member states to 
protect patents for microorganisms, non-biological and microbiological processes as 
well as determines what varieties of plants to be protected by patents or by an effective 
sui generis system or by a combination of both. (DEL NERO, 1998). 
Article 27.3 (b) of TRIPS conflicts with Article 8 (j) of the CBD, which states 
that each contracting party is obliged, in accordance with their national legislation, to: 
 
 
Respect, preserve and maintain knowledge, innovations and practices of local 
communities and indigenous peoples with traditional style relevant to the 
conservation and sustainable use of biological diversity life and also promote 
their wider application with the approval and involvement of the holders of 
such knowledge, innovations and practices and encourage the equitable 
sharing of benefits arising from the utilization of such knowledge, innovations 
and practices "(CBD, 1992). 
 
 
Therefore, the conflict is in the dispute that occurs between the 
aforementioned provisions of the two articles, "for there is an understanding among 
some countries that patents on genetic resources would not be compatible with 
national sovereignty and, thus, any patenting of life forms, including microorganisms 
should be prohibited " (ADAME et al.2008). 
Passos (2006, p.330) states on Article 8 of CBD that: The phrase contained in 
the caput of Article 8, "as far as possible", as well as the words "promote" and 
"encouraging", expressed in paragraph j, seem to remove the obligation of the precept, 
allowing such provisions to not be implemented as it would be desirable for the 
preservation of elements of biological diversity. 
Another point of contention regarding CBD concerns the transfer of 
technology. Within the CBD, access to genetic materials in developing countries by 
developed countries that are rich in technology and capital resources is conditioned on 
allowing access to resources by the former, and on the transfer of technologies for 
sustainable use of these resources, as well as the distribution of economic benefits by 
the latter. 
According to Mascanheras (2004, p.406), the issue of access to technology 
has proven to be problematic on two fronts: first, many developed countries such as 
the U.S. are refusing to adhere to this condition of the agreement, and second, the 
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technological gap and the lack of human and financial resources to devote to these 
research efforts in most developing countries have hindered a wider adoption of the 
principles of CBD. 
Another article of the Convention that causes controversy regarding the 
sovereignty of States over their natural resources is Article 22, first paragraph: "The 
provisions of this Convention shall not affect the rights and obligations of any 
Contracting Party deriving from any international agreement existing, unless the 
exercise of those rights and the fulfillment of these obligations cause serious injury or 
threat to biological diversity. " According to Passos (2006), this article "leaves open the 
possibility of other international agreements (which have not focused on the 
precautionary principle and, much less, environmental concerns) to have precedence 
over the CBD, for there is difficulties in scientific accuracies as to what in fact is 
considered potentially serious damage or threat to biological diversity. " 
As Passos observes, the sovereignty of States over their national resources, 
recognized by the CBD, merely gives to states the right to negotiate them (under 
international trade rules), but do not exempt them from the rules of market and 
multilateral trading systems such as the World Trade Organization (WTO). 
Nevertheless, Mascanheras (2004) suggests that developing countries can 
build strategies to defend their growth when threatened by the high standards set by 
TRIPS. Possible defense strategies are:  
 
• Exploring legal ambiguities:  
1. One of the strong limitations to meeting the high standards required in 
TRIPS is the rudimentary institutional infrastructure for the international intellectual 
property system and the need to coordinate with national systems, and only in some 
cases would the WTO infrastructure for dispute resolution would be able or available 
to equate these disputes; 
2. The structure of the law itself contains broad provisions that are not 
adequately addressed or implemented even in the WTO, thus opening up for different 
interpretations, which favors non-compliance as intended, given the ambiguities;  
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• Counterbalancing regulatory measures: in developing countries there is firstly 
the need to attract foreign direct investment and, secondly, there is dependence on 
external technologies, which may lead these countries to overestimate market 
mechanisms and also the sheer competition to the prejudice of their similarity to the 
strict regulation of TRIPS; 
 
• Safeguards Provisions: There are many blind spots for the coercive 
mechanisms by not adopting to the TRIPS, and strategies can stimulate the signatory 
countries, and especially the use of safeguards already provided in cases where 
application of the rule finds serious economic obstacles to their adoption, the law itself 
provides for adjustment periods, mainly in developing countries. 
 
In this context, to adjust the provisions of TRIPS to the principles of CBD, the 
conflict between the principles of the agreements shall be resolved through 
international negotiations, because the national legal and regulatory framework is 
reflective landmark international legal and normative. Many countries, perhaps for lack 
of preparation, end up simply transcribing the rules of the agreements, while failing to 
make a rule that prioritizes the needs and interests of their countries. 
Other countries, when trying to make rules for the use of and access to 
biodiversity and traditional knowledge resources, which both meet national interests 
and at the same time satisfy the principles of the agreements, eventually encounter 
unresolved tensions due to the differing stakes of various interest groups. For this 
reason, there is an urgent need to harmonize these agreements. 
 
 
4 BRAZILIAN LEGISLATION ADOPTING PRINCIPLES OF THE TRIPS 
 
As a WTO member, Brazil adopted to the principles of  TRIPS until 2000, the 
country was committed to implementing the necessary changes required by TRIPS, 
with the signing of the "Final Minutes of Multilateral Trade Negotiations in the Uruguay 
Round", in April 15, 1994 in Marrakech. To this end, new laws were introduced bringing 
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about important changes for agricultural biodiversity, as well as farmers and local and 
indigenous communities. 
In 1996, Law No. 9,279 (Industrial Property Law)was enacted to regulate 
intellectual property in Brazil, , amended by Law no. 10,196 of  February 14, 2001. On 
April 25, 1997, Law No. 9,456 (Plant Variety Protection Law - PVPL) was enacted, and 
regulated by Decree. 2,366, of November 5, 1997. (GERMAN-CASTELLI, 2004). 
The Industrial Property Law in Brazil, adapting to the precepts of TRIPS 
determines which inventions are susceptible of being patented, excepting those arising 
from discoveries, extracts and active ingredients isolated from plants. 
This means that the referenced legislation has determined that only 
pharmaceutical compositions containing extracts or active principles are patentable. 
The patenting of genetic material of animals and plants, such as genome and 
germplasm (except when differentiated from their state in nature) is prohibited, as it is 
considered as mere discovery, thus not fulfilling the requirement for patentability. 
(VIEIRA, BUAINAIN, SILVEIRA& VIEIRA JUNIOR, 2007).  
In Brazil, the Industrial Property Law expresses the power of who holds 
technology as well as international agreements, because the monopoly of use of a 
patent is 20 years, and of the utility model is 15 years (GERMAN-CASTELLI, 2004). 
With the entry into force of the Industrial Property Law, chemicals, medicines 
and food declared as inventions, as well as biotechnological processes resulting from 
new biotechnologies and transgenic microorganisms began to be patentable. 
However, Brazil does not "grant patent for natural living organisms, or parts thereof, 
even if isolated from nature, including its genome or germplasm." (GERMAN-
CASTELLI, 2004). 
According to Article 10, not considered an invention or utility model are: Item 
IX - all or part of natural living beings and biological materials found in nature or isolated 
therefrom, including the genome or germplasm of any natural living being and natural 
biological processes. Article 18 - not patentable are- all or part of living beings, except 
transgenic microorganisms meeting the three patentability requirements, which are not 
mere discoveries; Sole paragraph - For the purposes of this Act, transgenic 
microorganisms are organisms except all or part of plants or animals That express a 
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characteristic due to direct human intervention in their genetic composition that can not 
normally be achieved by the species. 
Regarding the Plant Variety Protection Act (Law No. 9.456/97), in the words of 
German-Castelli argues that the passage of this law was imperative to Brazil’s 
adherence to UPOV (International Union for the Protection of New Varieties of Plants 
Council). The Final Act of the Uruguay Round of GATT, approved by the Brazilian 
Congress through Decree 1355, provided in the TRIP (Agreement on Trade-Related 
Aspects of Intellectual Property including Real Fake) the adoption of sui generis 
systems for the protection of plant varieties by signatory countries (Art.27.3.b). 
This engagement did not involve the obligatory adherence to UPOV by Brazil. 
As a sui generis system does not necessarily coincide with the standards imposed by 
legislation of such entity. At the time, some nationalist sectors of the Brazilian scientific 
community recommend the franchise system (franchising) as the most appropriate 
profile for the Brazilian sui generis legislation. At the moment of decision, however, 
dominated the government's position that pointed the diplomatic isolation of the 
country, if not adhered to UPOV. 
For the Plant Variety Protection Act, the object of protection supervised by the 
right of the breeder is the cultivar (variety of any plant genus or species exceeding that 
is clearly distinguishable from other cultivars), known by a minimum margin of 
descriptors for your own denomination is homogeneous and stable - art. 3rd. LPC - 
(VIEIRA, BUAINAIN, VIEIRA JUNIOR & Silveira, 2007). 
In Brazil, the National Institute of Industrial Property (INPI) is a federal agency 
responsible for granting the registration of industrial property rights in the country. 
Among its responsibilities is the registration of technology transfer and nationwide 
business franchise contracts. In addition, INPI arbitrates the allocation of Conventions, 
Treaties and Agreements that deal with industrial property, and participates in debates 
and international negotiations. 
Applications for the registration of industrial property in Brazil must be filed with 
the INPI, with a detailed description of what to be registered among other specific 
requirements. Outside the country, the procedure may also be done through the INPI, 
which will make contact with other Industrial Property Offices and proceed with the 
application for registration under international law. 
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Before filing a patent with the INPI for e.g. a modified molecule, or a process 
of synthesis making use of biodiversity resources and traditional knowledge, several 
steps should first have been completed, namely: i) institutional accreditation by 
theBoard of Management of Genetic Patrimony (CGEN) to access and value (special 
license for collection and transportation of the material), ii) access authorization by the 
land owner or knowledge - informed consent; iii) if inflow forecast on Native Indian land 
it is necessary to request specific authorization from the National Indian Foundation - 
FUNAI, including obtaining the prior informed consent (pre-requisite to obtaining 
authorization from CGEN) of the indigenous community is possible, and, iv) Provision 
of Service contract in equity genetic and benefit sharing - registered in CGEN. 
According to Resolution no. 23/2006 of CGEN, the applicant of a patent 
product or process resulting from access to genetic heritage components must declare 
fulfill the conditions of Provisional Measure no. 2.186-16/01 and report the number and 
date of the corresponding access authorization, issued by CGEN. Resolution no. 
134/2006 of the INPI, in turn, explains this procedure, requiring the applicant to inform 
the INPI whether or not the request object has been obtained through access to the 
national genetic heritage (MATHIAS, 2008). 
 
 
5 THE BRAZILIAN LEGISLATION ON BIOLOGICAL DIVERSITY COMPLYING 
WITH PRINCIPLES OF CBD 
  
Brazil was one of the first signatories of the Convention on Biological Diversity. 
Brazil has actively participated in international negotiations and has been present in 
several international forums dealing with this issue. To meet the requirements of the 
CBD, changes in legislation have been implemented, such as Act No. 2186-16 of 2001 
and Decree No. 3.945 Measure 2001, as amended by Decree No. 4946 of 2003 which 
created the Board of Management of Genetic Heritage - CGEN (ASSAD & SAMPAIO, 
2005). 
The Brazilian Federal Constitution of 1988, Chapter on Environment, Article 
225, paragraph 1, item II, states that the government and the community have a duty 
to preserve the diversity and integrity of the genetic patrimony of the country and 
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supervise the institutions engaged in research and manipulation of genetic material. 
This means that the protection of genetic resources is at the height of the legal system 
of the country. This device was regulated by Law No. 9985 of July 18, 2000, which 
defines biological diversity. 
The Convention on Biological Diversity (CBD) was ratified in Brazil by Decree. 
2.519/98. Since signing the CBD, several attempts have been made to regulate the 
access to genetic resources. 
However, the entry into force of the Provisional Measure No. 2.186-16/01 
stops all projects in progress in national congress. In 2000, there were many protests 
from scientists and civil society in general, due to the operating contract for genetic 
resources of the Amazon between the social organization Bioamazônia - 
commissioned by the federal government to manage the Brazilian Program of 
Molecular Ecology for Sustainable Use Biodiversity of the Amazon - and the 
multinational corporation NOVARTIS PHARMA AG. Given these intricacies, the 
Executive Branch issued Provisional Measure No. 2.052/00, which was reissued 
without change monthly until April 2001, when it started to change until August 2001. 
However, since then, by virtue of Constitutional Amendment No. 32, dated September 
12, 2001, access to genetic resources and traditional knowledge in Brazil is regulated 
by Provisional Measure No. 2.186-16/01 in his 16th reissue ( Castilho, 2008) . 
This Provisional Measure was regulated by Decree No. 3,945, of September 
28, 2001, article 10, which defines the composition of the Board of Management of 
Genetic Patrimony (CGEN), a federal agency linked to the Ministry of Environment, 
and establishes the standards for their operation, and subsequently received updates 
through Decree No. 4946, of December 31, 2003. The Provisional Measure regulates 
the activities regarding access to genetic resources through Decrees, Resolutions, and 
Resolutions of the Technical Guidelines, the latter three approved by CGEN (ASSAD 
& Sampaio, 2005). 
In this context, it is important to mention the Law no. 11,105, March 24, 2005, 
establishing safety standards and mechanisms for monitoring activities involving 
genetically modified organisms - GMOs and their derivatives, creating the National 
Biosafety Council - CNBS, restructuring the National Technical Commission on 
Biosafety – CTNBio establishing a National Biosafety Policy - GNP and, for the purpose 
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of disciplinary sanctions against harmful conduct and activities to genetic resources or 
associated traditional knowledge. Decree No. 5,459, of June 7, 2005, regulated article 
30 of the Measure Provisional No. 2186-16. 
The Provisional Measure No. 2186-16 also ensures the rights of indigenous 
and local communities requiring an indication of the source of access to traditional 
knowledge in all publications, uses and exploitations. Moreover, it prohibits testing and 
research related to traditional knowledge by unauthorized third parties, as well as any 
dissemination, transmission or retransmission of data and information that comprises 
or is associated with traditional knowledge which is in the direct ownership of these 
communities (SANTILLI, 2007). 
For access to traditional knowledge or genetic heritage components for 
scientific research and technological development of bioprospecting activities, 
Provisional Measure No. 2.186-16/01 emphasizes that foreign groups, institutionally 
unaffiliated researchers or research agencies and individuals can only claim access to 
these resources if they are linked to a national research institution. 
Regarding the shipment of materials for research regulated by MP No. 2186-
16, the shipment of samples of components of genetic heritage destined for scientific 
research, bioprospecting or technological development must comply with the rules 
specified in the standard, while sending herbarium specimens for morphological 
analysis does not need to follow the specific regulations established by the MP. 
The most accentuated criticism of MP regards the consent of the holder of the 
area from which to remove the material for research and is based on the following 
arguments: difficulties in identifying individuals responsible for the area, in mapping the 
area where the material will be removed for research and, of course, the advancement 
of research to recognize the area firstly for the application for approval and secondly 
for material collection. However, the argument supporting this claim is the legal nature 
of the genetic heritage and the need to encourage the conservation of biodiversity. 
Due to the origin and nature of transaction costs and the limited rationality of 
agents, there is the risk that opportunistic behavior may not be accurately assessed 
nor the consequences of the behaviors of other actors involved in the transaction 
predicted. There is thus a need to create mechanisms that can minimize these 
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uncertainties by providing a flexible (contract?) structure that can adapt to 
unforeseeable circumstances. 
There are also uncertainties because genetic resources themselves are 
evolving. Because of this it is not known which properties will be useful in the near 
future. For this reason, there is also the difficulty of valuing these resources. Another 
important point is that no complete information is available and completed on the 
natural resources, which creates enormous difficulties related to the construction of 
contracts that can be met. 
In this context, the problematic definition of property rights leads to long-term 
returns being penalized through distortions in the investment profile. Investments are 
made in bioprospecting, mostly in various stages of research, from the collection of the 
input, the laboratory tests, the preclinical and clinical testing, until the final product 
reaches the consumer. All these stages are distinct and can be developed by different 
institutions or by a single institution. In this sense, the return associated with them 
depends on the maintenance of property rights, because any vagueness leads to 
increased uncertainty and contractual maintenance costs. 
In order to decrease this level of uncertainty, there is a need for contractual 
and organizational forms that are flexible, allowing for adaptations and changes during 
the process, thereby reducing transaction costs and increasing the interest of the 
parties to remain in the process.  
Since the CBD, many contracts have been signed. Despite the fact that the 
Convention clarifies a set of principles for the allocation of property rights relating to 
the use of genetic resources, bioprospecting negotiations are not always successful, 
either because contracts are not up to expectations in terms of financial returns, or 
because the agreements remain contradictory. 
 
 
CONCLUSION 
 
After examining the issue it is clear that the practice of bioprospecting brings 
in its wake a number of uncertainties, considering that the genetic resources 
themselves are evolving. Because of this it is not known which properties will be useful 
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in the near future. For this reason, there is also the difficulty of valuing these resources. 
Another point is there isn’t information available about traditional knowledge and all the 
natural resources, which creates enormous difficulty in drafting contracts that may be 
signed bilaterally. 
It should be stated that both during the drafting and signing of long-term 
agreements, there is a need for an effective advisory agency, particularly with regard 
to public property. Another key point to be observed in such contracts, is that 
institutions have the opportunity to develop contracts that are changeable and subject 
to renegotiation in the process, thereby reducing transaction costs and mitigating the 
uncertainties and risks of opportunism by the parties (in order to avoid repeating such 
occurrences as the illegal contracts signed between Bioamazônia and NOVARTIS 
PHARMA AG.) 
It is imperative that countries seek a balance between the conservation and 
sustainable use of the environment on the one hand, and scientific and technological 
interests and market forces on the other, and that Brazil, being a signatory to both 
agreements, seek only to sign contracts with other signatories to the Convention on 
Biological Diversity and the TRIPS respecting its principles. 
It is worth mentioning that there is real need to seek development that is 
economically sustainable and to align existing bioprospecting contracts with a new 
international law of the environment that incorporates both present and future 
concerns. 
Finally, as suggested by Rafael Costa Freiria (2003), international 
bioprospecting contracts offer the opportunity to set certain limits, such as in terms of 
mitigating contractual autonomy in choice of forum clauses to prevent fraud against 
jurisdictions that have more stringent environmental protection standards, discussing 
the pressing need for good faith in bioprospecting contracts in view of preserving the 
culture of local communities, as well as of achieving equality in the distribution of 
benefits from the exploitation of biodiversity. Such efforts would further the search of a 
situation of better balance between capital-owning investors and biotechnological 
mechanisms on the one hand, and the party that seeks equitable exploitation in their 
areas of biological diversity on the other. 
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